Table 2.

Definition of response (failure or warning) to first line TKI treatments, according to ELN 2013 recommendations (6). “Failure” mandates for a change of treatment. “Warning” warns that the response must be monitored more frequently.

		HEMATOLOGIC RESPONSE	CYTOGENETIC RESPONSE	MOLECULAR RESPONSE
FAILURE	3 months	Not full	None (Ph+ > 95%)
	6 months		Less than partial (Ph+>35%)	BCR-ABL >10%
	12 months		Less than complete (Ph+>0)	BCR-ABL >1%
WARNING	3 months		Minor/minimal (Ph+ 36–95%)	BCR-ABL >10%
	6 months		Partial (Ph+1–35%)	BCR-ABL 1–10%
	12 months			BCR-ABL 0.1–1%